<DOC>
	<DOCNO>NCT02375633</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-blinded , Parallel , Active-controlled , Phase III Clinical Trial Evaluate Efficacy Safety DW-330SR2 Pelubiprofen Chronic Back Pain Patients .</brief_summary>
	<brief_title>Phase 3 Study DW-330SR2 Pelubiprofen Chronic Back Pain Patients</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<criteria>More 12 week time trial start , low back pain require analgesia administration . Class 1 2 back pain patient along Quebec Task Force Classification Patients pain least 40mm test result visit2 The voluntary legal guardian 's write consent participate clinical trial subject Severe gastrointestinal disease , heart disease , high blood pressure patient Patients secondary cause obvious Within 24 week patient back surgery clinical trial participation Within 4 week patient experience psychotropic drug , narcotic analgesic dosage may affect pain sensation Within 4 week patient treated steroid drug oral injection Within 2 week patient treat MAO inhibition drug Patients severe respiratory depression status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>